摘要
目的探讨经肝动脉插管栓塞化疗术(TACE)联合射频消融术(RFA)治疗原发性肝癌的近期临床效果及远期预后。方法选取85例原发性肝癌患者的临床资料进行回顾性分析,根据治疗方法的不同将患者分为TACE组40例、联合组(TACE+RFA)45例,对比两组患者的临床疗效及预后。结果治疗后,联合组患者的近期疗效总有效率为71.11%,高于TACE组的50.00%(P﹤0.05);治疗后,联合组患者的血清AFP水平明显低于TACE组(P﹤0.01),两组的KPS评分比较,差异无统计学意义(P﹥0.05);随访3年,联合组失访2例,TACE组失访3例,联合组患者的3年生存率为28.89%(13/45),TACE组患者的3年生存率为15.00%(6/40),两组比较,差异无统计学意义(P﹥0.05),联合组的中位生存时间为25个月,长于TACE组的19个月(P﹤0.05);两组患者并发症发生率比较,差异无统计学意义(P﹥0.05)。结论 TACE联合RFA治疗原发性肝癌的临床效果优于单用TACE治疗。
Objective To investigate the clinical efficacy, as well as the short-and long-term outcome of transcatheter arterial chemoembolization（TACE） combined with radiofrequency ablation（RFA） in the treatment of primary hepatocellular carcinoma（HCC）. Method A total of 85 cases of primary HCC were retrospectively analyzed, in which 40 cases were treated with TACE（TACE group）, and 45 cases were given combined therapy（TACE ＋ RFA）, the clinical efficacy and prognosis in the two groups were compared. Result The short-term overall response rate of the combined therapy group was 71.11%, significantly higher than that in TACE group at 50.00%（P〈0.05）; after treatment, the serum AFP level in combined therapy group was lower than that of TACE group（P〈0.01）, while there were no significant difference in regard of KPS score between the two groups（P〈0.05）; after 3 years of follow-up, there were 2 cases in combined therapy group, and 3 cases in TACE group that lost follow up, and the 3-year survival rate was 28.89%（13/45） in the combined therapy group and was 15.00%（6/40） in the TACE group, with no significant difference observed between the two groups（P〈0.05）, as for median survival time, it was 25 months vs 19 months between combined therapy group and TACE group（P〈0.05）; the incidence of adverse reactions were comparable in the two groups（P〈0.05）. Conclusion TACE combined with RFA is superior to TACE alone in the treatment of primary HCC.
出处
《癌症进展》
2017年第12期1457-1459,共3页
Oncology Progress
关键词
经肝动脉插管栓塞化疗术
射频消融术
原发
肝癌
预后
transcatheter arterial chemoembolization
radiofrequency ablation
primary
hepatocellular carcinoma
prognosis
